MAKO Surgical Corp. (NASDAQ:MAKO) today announced it ranked No. 1 on Deloitte’s Technology Fast 500™, ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. MAKO’s president and chief executive officer, Maurice R. Ferré, M.D., attributes MAKO’s success to the exceptionally talented team members who have been instrumental in developing, commercializing and supporting its innovative robotic arm technology and implant systems. “Our commitment to provide solutions for the treatment of osteoarthritis that focus on restoring patients’ quality of life has been and will continue to be the driving force in our growth,” said Maurice R. Ferré. “We are honored to be recognized among Deloitte’s Technology Fast 500TM.\"

“MAKO, like all 2011 Technology Fast 500™ companies, has excelled in fostering innovation and channeling it into spectacular growth -- against the backdrop of one of the most challenging economies in history,” said Eric Openshaw, vice chairman and U.S. technology, media and telecommunications leader, Deloitte LLP. \"Deloitte recognizes MAKO for its remarkable accomplishment.”
“We are pleased to honor MAKO as a 2011 Technology Fast 500 company,” said Mark Jensen, managing partner, technology and venture capital services, Deloitte & Touche LLP. “As one of the fastest growing tech companies in North America, MAKO has demonstrated excellence in technological innovation, entrepreneurship and rapid growth.” About Deloitte’s 2011 Technology Fast 500™ Technology Fast 500, which was conducted by Deloitte & Touche LLP, a subsidiary of Deloitte LLP, provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies – both public and private - in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2006 to 2010. In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company\'s operating revenues. Companies must have base-year operating revenues of at least $50,000 USD or CD, and current-year operating revenues of at least $5 million USD or CD. Additionally, companies must be in business for a minimum of five years, and be headquartered within North America. About MAKO Surgical Corp. MAKO Surgical Corp. is a medical device company that markets both its RIO® Robotic-Arm Interactive Orthopedic system and its proprietary RESTORIS® implants for orthopedic knee and hip procedures called MAKOplasty®. The RIO is a surgeon-interactive tactile surgical platform that incorporates a robotic arm and patient-specific visualization technology, which enables precise, consistently reproducible bone resection for the accurate insertion and alignment of MAKO\'s RESTORIS implants. The MAKOplasty solution is comprised of technologies enabled by an intellectual property portfolio including more than 300 U.S. and foreign, owned and licensed, patents and patent applications. Additional information can be found at ckalb@makosurgical.com